301 related articles for article (PubMed ID: 36482957)
1. The emergence of SARS-CoV-2 Omicron subvariants: current situation and future trends.
Farahat RA; Abdelaal A; Umar TP; El-Sakka AA; Benmelouka AY; Albakri K; Ali I; Al-Ahdal T; Abdelazeem B; Sah R; Rodriguez-Morales AJ
Infez Med; 2022; 30(4):480-494. PubMed ID: 36482957
[TBL] [Abstract][Full Text] [Related]
2. Omicron (BA.1) and sub-variants (BA.1.1, BA.2, and BA.3) of SARS-CoV-2 spike infectivity and pathogenicity: A comparative sequence and structural-based computational assessment.
Kumar S; Karuppanan K; Subramaniam G
J Med Virol; 2022 Oct; 94(10):4780-4791. PubMed ID: 35680610
[TBL] [Abstract][Full Text] [Related]
3. Unique mutations in SARS-CoV-2 Omicron subvariants' non-spike proteins: Potential impacts on viral pathogenesis and host immune evasion.
Hossain A; Akter S; Rashid AA; Khair S; Alam ASMRU
Microb Pathog; 2022 Sep; 170():105699. PubMed ID: 35944840
[TBL] [Abstract][Full Text] [Related]
4. Immune Evasion of SARS-CoV-2 Omicron Subvariants.
Ke H; Chang MR; Marasco WA
Vaccines (Basel); 2022 Sep; 10(9):. PubMed ID: 36146623
[TBL] [Abstract][Full Text] [Related]
5. The evolution of the spike protein and hACE2 interface of SARS-CoV-2 omicron variants determined by hydrogen bond formation.
Yang YY; Tseng YJ
Brief Funct Genomics; 2023 May; 22(3):291-301. PubMed ID: 36723978
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 Omicron subvariants exhibit distinct fusogenicity, but similar sensitivity, to pan-CoV fusion inhibitors.
Xia S; Wang L; Jiao F; Yu X; Xu W; Huang Z; Li X; Wang Q; Zhu Y; Man Q; Jiang S; Lu L
Emerg Microbes Infect; 2023 Dec; 12(1):2178241. PubMed ID: 36748716
[TBL] [Abstract][Full Text] [Related]
7. Structural Basis for the Enhanced Infectivity and Immune Evasion of Omicron Subvariants.
Li Y; Shen Y; Zhang Y; Yan R
Viruses; 2023 Jun; 15(6):. PubMed ID: 37376697
[TBL] [Abstract][Full Text] [Related]
8. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission.
Shrestha LB; Foster C; Rawlinson W; Tedla N; Bull RA
Rev Med Virol; 2022 Sep; 32(5):e2381. PubMed ID: 35856385
[TBL] [Abstract][Full Text] [Related]
9. Editorial: World Health Organization (WHO) Variants of Concern Lineages Under Monitoring (VOC-LUM) in Response to the Global Spread of Lineages and Sublineages of Omicron, or B.1.1.529, SARS-CoV-2.
Parums DV
Med Sci Monit; 2022 Jul; 28():e937676. PubMed ID: 35775166
[TBL] [Abstract][Full Text] [Related]
10. Omicron (B.1.1.529) variant and its subvariants and lineages may lead to another COVID-19 wave in the world? -An overview of current evidence and counteracting strategies.
Sah R; Rais MA; Mohanty A; Chopra H; Chandran D; Bin Emran T; Dhama K
Int J Surg Open; 2023 Jun; 55():100625. PubMed ID: 37255735
[TBL] [Abstract][Full Text] [Related]
11. The Epidemiological Features of the SARS-CoV-2 Omicron Subvariant BA.5 and Its Evasion of the Neutralizing Activity of Vaccination and Prior Infection.
Tian D; Nie W; Sun Y; Ye Q
Vaccines (Basel); 2022 Oct; 10(10):. PubMed ID: 36298564
[TBL] [Abstract][Full Text] [Related]
12. Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5.
Kimura I; Yamasoba D; Tamura T; Nao N; Suzuki T; Oda Y; Mitoma S; Ito J; Nasser H; Zahradnik J; Uriu K; Fujita S; Kosugi Y; Wang L; Tsuda M; Kishimoto M; Ito H; Suzuki R; Shimizu R; Begum MM; Yoshimatsu K; Kimura KT; Sasaki J; Sasaki-Tabata K; Yamamoto Y; Nagamoto T; Kanamune J; Kobiyama K; Asakura H; Nagashima M; Sadamasu K; Yoshimura K; Shirakawa K; Takaori-Kondo A; Kuramochi J; Schreiber G; Ishii KJ; ; Hashiguchi T; Ikeda T; Saito A; Fukuhara T; Tanaka S; Matsuno K; Sato K
Cell; 2022 Oct; 185(21):3992-4007.e16. PubMed ID: 36198317
[TBL] [Abstract][Full Text] [Related]
13. Structural Characteristics of Heparin Binding to SARS-CoV-2 Spike Protein RBD of Omicron Sub-Lineages BA.2.12.1, BA.4 and BA.5.
Shi D; Bu C; He P; Song Y; Dordick JS; Linhardt RJ; Chi L; Zhang F
Viruses; 2022 Dec; 14(12):. PubMed ID: 36560700
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 Omicron Subvariants Do Not Differ Much in Binding Affinity to Human ACE2: A Molecular Dynamics Study.
Nguyen HL; Nguyen TQ; Li MS
J Phys Chem B; 2024 Apr; 128(14):3340-3349. PubMed ID: 38564480
[TBL] [Abstract][Full Text] [Related]
15. The rapid rise of SARS-CoV-2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants.
Ao D; He X; Hong W; Wei X
MedComm (2020); 2023 Apr; 4(2):e239. PubMed ID: 36938325
[TBL] [Abstract][Full Text] [Related]
16. Nanomolar anti-SARS-CoV-2 Omicron activity of the host-directed TMPRSS2 inhibitor N-0385 and synergistic action with direct-acting antivirals.
Pérez-Vargas J; Lemieux G; Thompson CAH; Désilets A; Ennis S; Gao G; Gordon DG; Schulz AL; Niikura M; Nabi IR; Krajden M; Boudreault PL; Leduc R; Jean F
Antiviral Res; 2024 May; 225():105869. PubMed ID: 38548023
[TBL] [Abstract][Full Text] [Related]
17. Impact of mutations defining SARS-CoV-2 Omicron subvariants BA.2.12.1 and BA.4/5 on Spike function and neutralization.
Pastorio C; Noettger S; Nchioua R; Zech F; Sparrer KMJ; Kirchhoff F
iScience; 2023 Nov; 26(11):108299. PubMed ID: 38026181
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 Omicron Variant Genomic Sequences and Their Epidemiological Correlates Regarding the End of the Pandemic: In Silico Analysis.
Kumar A; Asghar A; Singh HN; Faiq MA; Kumar S; Narayan RK; Kumar G; Dwivedi P; Sahni C; Jha RK; Kulandhasamy M; Prasoon P; Sesham K; Kant K; Pandey SN
JMIR Bioinform Biotechnol; 2023; 4():e42700. PubMed ID: 36688013
[TBL] [Abstract][Full Text] [Related]
19. Genome Evolution and Early Introductions of the SARS-CoV-2 Omicron Variant in Mexico.
Castelán-Sánchez HG; Martínez-Castilla LP; Sganzerla-Martínez G; Torres-Flores J; López-Leal G
Virus Evol; 2022; 8(2):veac109. PubMed ID: 36582501
[TBL] [Abstract][Full Text] [Related]
20. Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages.
Xia S; Wang L; Zhu Y; Lu L; Jiang S
Signal Transduct Target Ther; 2022 Jul; 7(1):241. PubMed ID: 35853878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
